NYSTATIN

Posology Oral Candidiasis Infants (1 month to 2 years) 1ml should be dropped into the mouth four times a day. Children (≥ 2 years) and adults For the treatment of denture sores, and oral infections in children (≥ 2 years) and adults caused by candidas albicans.

1ml of the suspension should be dropped into the mouth four times daily; it should be kept in contact with the affected areas as long as possible. Intestinal candidiasis Infants (1 month to 2 years) 1ml should be dropped into the mouth four times a day.

Adults For the treatment of intestinal candidosis 5ml of the suspension should be dropped into the mouth four times daily. Paediatric population (≥ 2 years) 1ml should be dropped into the mouth four times a day. For prophylaxis a total daily dosage of 1 million units has been found to suppress the overgrowth of candidas albicans in patients receiving broad- spectrum antibiotic therapy.

For prophylaxis in the newborn the suggested dose is 1ml once daily. The longer the suspension is kept in contact with the affected area in the mouth before swallowing, the greater will be its effect. Administration should be continued for 48 hours after clinical cure to prevent relapse.

Older people No specific dosage recommendations or precautions. If signs and symptoms worsen or persist (beyond 14 days of treatment), the patient should be reevaluated, and alternate therapy considered.

Nystatin is generally well tolerated by all age groups, even during prolonged use. If irritation or sensitisation develops, treatment should be discontinued. Nausea has been reported occasionally during therapy. Large oral doses of Nystatin have occasionally produced diarrhoea, gastrointestinal distress,nausea and vomiting.

Rash, including urticaria has been reported rarely. Steven-Johnson Syndrome has been reported very rarely. Hypersensitivity and angioedema, including facial oedema have been reported. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.

It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard.

Nystatin Oral Suspension BP contains sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine. This should also be taken into account in patients with diabetes mellitus.

3 mg) sodium per 1 ml dose. To be taken into consideration by patients on a controlled sodium diet. Nystatin Oral Suspension contains sodium metabisulphite (E223) which may rarely cause severe hypersensitivity reactions and bronchospasm.

Nystatin Oral Suspension contains propyl p-hydroxybenzoate and methyl p- hydroxybenzoate which may cause allergic reactions (possibly delayed). Nystatin oral preparations should not be used for treatment of systemic mycoses.

1.